| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma (NCT05137886) | Institute of Hematology & Blood Diseases Hospital, China | 2022-01-01 |
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (NCT04871607) | City of Hope Medical Center | 2021-11-02 |
| RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT (NCT04776265) | Grupo Argentino de Tratamiento de la Leucemia Aguda | 2021-06-01 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCT04640779) | Mayo Clinic | 2021-02-08 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (NCT04681105) | City of Hope Medical Center | 2020-11-18 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT04052997) | ADC Therapeutics S.A. | 2019-09-13 |
| Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma (NCT04134325) | UNC Lineberger Comprehensive Cancer Center | 2019-09-01 |
| Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma (NCT03730363) | Reinhold Munker | 2018-12-19 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03739619) | Emory University | 2018-11-26 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741) | Mayo Clinic | 2018-03-27 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT03013933) | City of Hope Medical Center | 2017-05-03 |
| Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma (NCT03057795) | City of Hope Medical Center | 2017-04-03 |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant (NCT02869633) | Vanderbilt-Ingram Cancer Center | 2016-11-01 |
| Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02744612) | City of Hope Medical Center | 2016-06-20 |
| Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT02824029) | Barbara Ann Karmanos Cancer Institute | 2016-06-01 |
| Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02254239) | Mayo Clinic | 2016-02-04 |
| INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma (NCT02456675) | Incyte Corporation | 2015-06-01 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02227199) | University of Washington | 2014-10-10 |
| Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (NCT01921387) | Fred Hutchinson Cancer Center | 2013-10-09 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012) | National Cancer Institute (NCI) | 2013-07-17 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma (NCT01703949) | University of Washington | 2013-03-20 |
| Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (NCT01701986) | M.D. Anderson Cancer Center | 2012-10-25 |
| Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (NCT01393717) | City of Hope Medical Center | 2011-10-20 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (NCT00860171) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer (NCT00789776) | Fred Hutchinson Cancer Center | 2008-10-13 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (NCT00075478) | Fred Hutchinson Cancer Center | 2003-10-01 |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma (NCT00005803) | Fred Hutchinson Cancer Center | 1999-09-01 |